Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGM-6268 in Healthy Adults and Mild to Moderate COVID-19
NCT05184218Phase 1Terminated
- Sponsor
- IGM Biosciences
- Start
- Jan 2022
- Primary completion
- May 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IGM-6268 in coronavirus disease 2019 (COVID-19) (7 arms), sponsored by IGM Biosciences. Primary endpoint: Number, severity, and type of adverse events per CTCAE 5.0. Started Jan 2022; status: terminated.
02
Drugs
IGM-6268
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05184218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05184218.